Uncategorized

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

2seventy bio, Inc., announced the completion of the asset purchase agreement by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron Read More »

Scroll to Top